Lisanti Capital Growth’s Alnylam Pharmaceuticals ALNY Stock Holding History

Lisanti Capital Growth’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-9,285	Closed	-$1.38M	–	115
2020 Q2	$1.38M	Buy	9,285 +4,031	+77%	+$543K	0.28%	101
2020 Q1	$572K	Buy	5,254 +159	+3%	+$18.4K	0.19%	104
2019 Q4	$587K	Buy	+5,095	New	+$508K	0.16%	109
2014 Q3	–	Sell	-9,140	Closed	-$577K	–	94
2014 Q2	$577K	Buy	+9,140	New	+$543K	0.26%	92
2014 Q1	–	Sell	-15,140	Closed	-$974K	–	98
2013 Q4	$974K	Sell	15,140 -20,384	-57%	-$1.22M	0.41%	87
2013 Q3	$2.27M	Buy	35,524 +5,155	+17%	+$257K	1.04%	41
2013 Q2	$1.4M	Buy	+30,369	New	+$808K	0.67%	63

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Lisanti Capital Growth's ALNY Position: Q3 2020 in Review

Lisanti Capital Growth sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2020, closing a stake of 9,285 shares — an estimated $1.38M sold.

Lisanti Capital Growth first reported a position in ALNY in Q2 2013 and held it in 7 quarters. The position peaked at $2.27M in Q3 2013. 357 funds tracked by Wall St. Rank hold ALNY as of Q3 2020.

Lisanti Capital Growth reported no remaining Alnylam Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Lisanti Capital Growth sold 9,285 Alnylam Pharmaceuticals shares in Q3 2020, an estimated $1.38M.
Lisanti Capital Growth first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 7 quarters.
Lisanti Capital Growth's Alnylam Pharmaceuticals position peaked at $2.27M in Q3 2013.
357 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2020.

Based on Lisanti Capital Growth's 13F filing for Q3 2020, filed 5 Nov 2020.